Axsome Therapeutics Inc (NAS:AXSM)

$ 89.24 1.99 (2.28%) Market Cap: 4.28 Bil Enterprise Value: 4.06 Bil PE Ratio: 0 PB Ratio: 41.51 GF Score: 39/100

Q2 2024 Axsome Therapeutics Inc Earnings Call Transcript
Aug 05, 2024

$83.21 (-1.43%)

Earnings
Q1 2024 Axsome Therapeutics Inc Earnings Call Transcript
May 06, 2024

$75.94 (+1.52%)

Earnings
Q4 2023 Axsome Therapeutics Inc Earnings Call Transcript
Feb 20, 2024

$81.14 (-12.57%)

Earnings
Axsome Therapeutics Inc Solriamfetol Investor Day Transcript
Dec 07, 2023
Q3 2023 Axsome Therapeutics Inc Earnings Call Transcript
Nov 06, 2023

$62.42 (-4.18%)

Earnings
Axsome Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Q2 2023 Axsome Therapeutics Inc Earnings Call Transcript
Aug 07, 2023

$71.09 (-3.49%)

Earnings
Axsome Therapeutics Inc at Bank of America Global Healthcare Conference Transcript
May 11, 2023
Q1 2023 Axsome Therapeutics Inc Earnings Call Transcript
May 08, 2023

$77.73 (+5.41%)

Earnings
Axsome Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 20, 2023
Q4 2022 Axsome Therapeutics Inc Earnings Call Transcript
Feb 27, 2023

$64.08 (+4.96%)

Earnings
Q3 2022 Axsome Therapeutics Inc Earnings Call Transcript
Nov 07, 2022

$56.82 (-0.47%)

Earnings
Axsome Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022
Axsome Therapeutics Inc Auvelity FDA Approval Call Transcript
Aug 19, 2022
Q2 2022 Axsome Therapeutics Inc Earnings Call Transcript
Aug 09, 2022

$44.76 (+3.35%)

Earnings
Axsome Therapeutics Inc Sunosi® Investor Update Transcript
Jun 28, 2022
Q1 2022 Axsome Therapeutics Inc Earnings Call Transcript
May 02, 2022

$34.04 (+7.21%)

Earnings
Axsome Therapeutics Inc to Discuss the Acquisition of Sunosi from Jazz Pharmaceuticals PLC- Conference Call Transcript
Mar 28, 2022
Axsome Therapeutics Inc at Needham Neuroscience Forum (Virtual) Transcript
Mar 16, 2022
Q4 2021 Axsome Therapeutics Inc Earnings Call Transcript
Mar 01, 2022

$30.98 (+10.21%)

Earnings
Q3 2021 Axsome Therapeutics Inc Earnings Call Transcript
Nov 08, 2021

$43.36 (+7.86%)

Earnings
Q2 2021 Axsome Therapeutics Inc Earnings Call Transcript
Aug 09, 2021

$27.37 (-46.50%)

Earnings
Axsome Therapeutics Inc at William Blair Biotech Focus Conference (Virtual) Transcript
Jul 15, 2021
Axsome Therapeutics Inc at UBS Global Healthcare Virtual Conference Transcript
May 24, 2021
Axsome Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 11, 2021
Q1 2021 Axsome Therapeutics Inc Earnings Call Transcript
May 10, 2021

$54.39 (-4.51%)

Earnings
Axsome Therapeutics Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 01, 2021
Q4 2020 Axsome Therapeutics Inc Earnings Call Transcript
Mar 01, 2021

$69.2 (+2.73%)

Earnings
Q3 2020 Axsome Therapeutics Inc Earnings Call Transcript
Nov 05, 2020

$69.51 (-6.99%)

Earnings
Axsome Therapeutics Inc AXS-12 Update Corporate Call Transcript
Sep 21, 2020
Axsome Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 17, 2020
Q2 2020 Axsome Therapeutics Inc Earnings Call Transcript
Aug 10, 2020

$81.79 (+4.76%)

Earnings
Axsome Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 05, 2020
Q1 2020 Axsome Therapeutics Inc Earnings Call Transcript
May 08, 2020

$87.97 (-4.19%)

Earnings
Axsome Therapeutics Inc - To Discuss the Topline Results of the ADVANCE-1 trial of AXS-05 in Alzheimer's Disease Agitation - Conference Call Transcript
Apr 27, 2020
Axsome Therapeutics Inc Corporate Call to Discuss the Topline Results of the INTERCEPT Trial of AXS-07 Transcript
Apr 06, 2020
Axsome Therapeutics Inc AXS-05 STRIDE-1 Results Conference Call Transcript
Mar 30, 2020
Q4 2019 Axsome Therapeutics Inc Earnings Call Transcript
Mar 12, 2020

$64.78 (-12.04%)

Earnings
Axsome Therapeutics Inc Enters into Exclusive License Agreement with Pfizer Inc Conference Call Transcript
Jan 13, 2020
Axsome Therapeutics Inc AXS-07 MOMENTUM Results Conference Call Transcript
Dec 30, 2019
Axsome Therapeutics Inc AXS-05 GEMINI Results Conference Call Transcript
Dec 16, 2019
Axsome Therapeutics Inc AXS-12 CONCERT Results Call Transcript
Dec 03, 2019
Axsome Therapeutics Inc Investor R&D Call with Migraine Key Opinion Leaders (KOLs) Focusing on AXS-07 Transcript
Nov 25, 2019
Q3 2019 Axsome Therapeutics Inc Earnings Call Transcript
Nov 07, 2019

$23.27 (-9.67%)

Earnings
Axsome Therapeutics Inc at Morgan Stanley Healthcare Conference Transcript
Sep 11, 2019
Q2 2019 Axsome Therapeutics Inc Earnings Call Transcript
Aug 08, 2019

$25.5 (+2.41%)

Earnings
Q1 2019 Axsome Therapeutics Inc Earnings Call Transcript
May 09, 2019

$19.81 (+0.87%)

Earnings

Axsome Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 03:40PM GMT

Release Date Price: $62.27 (+0.32%)

Transcript

Vikram Purohit

Morgan Stanley, Research Division - Equity Analyst

Thanks, everyone, for joining. This is a fireside chat with Axsome Therapeutics. Let me read a brief disclosure statement before we get started. So for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. My name is Vikram Purohit. I'm one of the biotech analysts with the research team. Happy to have with me Herriot Tabuteau, CEO; and Mark Jacobson, COO of Axsome. Thanks for joining us.

Herriot Tabuteau

Axsome Therapeutics, Inc. - Founder, Chairman, CEO & President

Thank you.

Questions & Answers

Vikram Purohit

Morgan Stanley, Research Division - Equity Analyst

So before we get into any specifics around pipeline Auvelity et cetera. Herriot, do you want to just level set for the audience and just provide a recap of some of the key milestones Axsome through work to do

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.